摘要
目的观察利拉鲁肽在初诊的肥胖2型糖尿病患者中的疗效。方法初诊的肥胖2型糖尿病患者,分别予以利拉鲁肽1.2 mg、1.8 mg皮下注射,每日1次,连续3个月。治疗前后观察患者HbA1C、血糖、体重、收缩压及LDL的变化。结果治疗后,患者HbA1C、血糖、体重、收缩压、血脂较治疗前均有改善。结论利拉鲁肽作为肥胖的2型糖尿病患者的初始治疗安全有效。
Objective To observe the efficacy of liraglutide in newly diagnosed obese patients with type 2 diabetes. Methods Newly diagnosed obese type 2 diabetes patients, were treated with liraglutide 1.2mg or 18mg respectively subcutaneous injection daily for three consecutive months. The HbA1 C, blood glucose, body weight, systolic blood pressure, and LDL of patients was detected before and after treatment. Results After treatment, the HbA1C, blood glucose, body weight and systolic blood pressure of patients were improved. Conclusion Liraglutide is safe and effective in the initial treatment of obese type 2 diabetes patients.
出处
《延安大学学报（医学科学版）》
2013年第4期17-18,22,共3页
Journal of Yan'an University:Medical Science Edition
